Suresh K. Durgam - Jan 18, 2022 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)

Role: Chief Medical Officer
Signature: /s/ Lawrence J. Hineline, Attorney-in-fact
Stock symbol: ITCI
Transactions as of: Jan 18, 2022
Transactions value $: -$261,553
Form type: 4
Date filed: 1/20/2022, 03:07 PM
Previous filing: Jan 11, 2022
Next filing: Feb 23, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ITCI	Common Stock	Sale	-$262K	-6.22K	-21.22%	$42.03	23.1K	Jan 18, 2022	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2021.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.92 to $42.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.

Content

This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2021.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.92 to $42.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.